What is Castle Biosciences's clinical studies?

Castle Biosciences (CSTL) reported clinical studies of $2.72M in Q1 2026.

How has Castle Biosciences's clinical studies changed year-over-year?

Castle Biosciences's clinical studies increased by 6.1% year-over-year, from $2.56M to $2.72M.

What is the long-term trend for Castle Biosciences's clinical studies?

Over 5 years (2020 to 2025), Castle Biosciences's clinical studies has grown at a 50.4% compound annual growth rate (CAGR), from $348K to $2.67M.

Castle Biosciences CSTL Clinical studies

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept cstl:AccruedClinicalStudiesCurrent.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's clinical studies.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's clinical studies?: Castle Biosciences (CSTL) reported clinical studies of $2.72M in Q1 2026.
How has Castle Biosciences's clinical studies changed year-over-year?: Castle Biosciences's clinical studies increased by 6.1% year-over-year, from $2.56M to $2.72M.
What is the long-term trend for Castle Biosciences's clinical studies?: Over 5 years (2020 to 2025), Castle Biosciences's clinical studies has grown at a 50.4% compound annual growth rate (CAGR), from $348K to $2.67M.